VKTX Viking Therapeutics Inc.

+0.28  (+4%)
Previous Close 6.55
Open 6.67
Price To Book 1.71
Market Cap 493,198,603
Shares 72,210,630
Volume 1,475,102
Short Ratio
Av. Daily Volume 1,361,718

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 2H 2019.
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
Acute Hip Fracture

Latest News

  1. 3 Top Small-Cap Stocks to Buy in August
  2. Is Viking Therapeutics a Buy?
  3. Edited Transcript of VKTX earnings conference call or presentation 1-Aug-19 8:30pm GMT
  4. Viking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript
  5. Where Will Viking Therapeutics Be in 1 Year?
  6. VKTX: Awaiting Feedback from FDA regarding pre-IND submission; Phase 2b trial in NASH expected to initiate 2H19…
  7. Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  8. Options Traders Load Up On VKTX Calls Ahead of Earnings
  9. Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
  10. Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
  11. Here’s What Hedge Funds Think About Viking Therapeutics, Inc. (VKTX)
  12. How Viking Therapeutics Is Positioned
  13. What Analysts Recommend for CBAY and VKTX
  14. 3 Stocks to Buy and Hold for the Next 50 Years
  15. Viking Therapeutics to Participate in Upcoming Investor Conferences
  16. 3 Small-Cap Biotech Stocks You Can Buy Right Now
  17. Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
  18. Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
  19. Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
  20. 3 Top Biotech Stocks to Buy in May